- freely available
Viruses 2012, 4(11), 2786-2805; doi:10.3390/v4112786
Published: 6 November 2012
Abstract: Lymphocytic choriomeningitis virus (LCMV) has contributed to unveil some of the molecular mechanisms of lethal mutagenesis, or loss of virus infectivity due to increased mutation rates. Here we review these developments, and provide additional evidence that ribavirin displays a dual mutagenic and inhibitory activity on LCMV that can be relevant to treatment designs. Using 5-fluorouracil as mutagenic agent and ribavirin either as inhibitor or mutagen, we document an advantage of a sequential inhibitor-mutagen administration over the corresponding combination treatment to achieve a low LCMV load in cell culture. This advantage is accentuated in the concentration range in which ribavirin acts mainly as an inhibitor, rather than as mutagen. This observation reinforces previous theoretical and experimental studies in supporting a sequential inhibitor-mutagen administration as a possible antiviral design. Given recent progress in the development of new inhibitors of arenavirus replication, our results suggest new options of ribavirin-based anti-arenavirus treatments.
1. Introduction: complexity of LCMV populations
Michael B.A. Oldstone wrote that “LCMV has proven to be a Rosetta stone for uncovering numerous phenomena in virology and immunology”. The several crucial achievements were listed by Oldstone in an introduction to an outstanding compilation of review articles on arenavirus biology . Yet, arenaviruses pose important challenges regarding the mechanism of replication and regulation of gene expression of a segmented genome, as well as disease mechanisms, prevention and treatment. Persistent arenavirus infections are highly prevalent among rodents, and when some of the viruses infect humans they may cause severe disease, including hemorrhagic fevers [2,3,4]. The prototypic arenavirus LCMV is increasingly regarded as a neglected human pathogen [5,6,7,8]. Unfortunately, the number of preventive or therapeutic possibilities for arenavirus-associated disease is very restricted. Despite promising developments [9,10,11,12], no licensed vaccines are generally available, and current therapy is essentially limited to an off-label use of the antiviral agent ribavirin (1-β-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) (Rib) [13,14]. This is why arenavirus-related diseases are an interesting target to explore new antiviral designs.
Lack of effective vaccines and antiviral treatments is a general difficulty for diseases associated with highly variable RNA viruses, due to quasispecies dynamics . The root of the problem is that mutations occur at such a high rate during RNA genome replication that even what is generally termed the “wild type” virus is, at any time, an average of a multitude of sequences. Although our attention is often fixed on a consensus sequence or on specific mutants identified in mutant spectra, in reality we deal with mutant clouds of rather indeterminate composition despite transient dominance of some specific mutant residues. Analyses of mutant spectra by ultra-deep sequencing have confirmed the extreme complexity of viral populations in nature, in support of previous evidence obtained by molecular cloning and sequencing ([16,17], among other examples ). LCMV participates of high mutation rates and quasispecies dynamics, with a direct implication in viral persistence and disease ([18,19,20,21,22,23,24,25,26,27,28,29,30,31,32]; reviews in [33,34]). The range of mutation frequencies calculated with genomes sampled from mutant spectra of LCMV populations passaged in cell culture in absence of mutagenic agents is in the range of 1.0 × 10-4 to 7.5 × 10-4 substitutions per nucleotide (s × nt-1), and mutation frequencies reached 3.6 × 10-3 and 1.1 × 10-3 s × nt-1 when the virus was passaged in the presence of 5-fluorouracil (FU) or Rib, respectively [35,36,37,38,39,40]. Mutation frequencies are in agreement with values of Shannon entropy, a measure of the proportion of different sequences in a genome distribution. Both parameters are used to quantify the complexity of mutant spectra, which is influenced by the number of passages from a clonal origin (i.e. starting with a plaque-purified virus), the multiplicity of infection (MOI), and the viral gene analyzed. Several studies indicate that the complexities of mutant spectra of LCMV are comparable to those determined for other RNA viruses .
2. Contributions of LCMV to lethal mutagenesis
Mutations often entail a fitness cost, and this applies also to drug-escape mutants. The almost systematic selection of drug-resistant viral mutants can be explained by the existence of multiple pathways to resistance, some with limited fitness cost (under a genomic sequence context or a given environment), and to the selection of compensatory (fitness-enhancing) mutations in viral genomes that continue expressing the resistance phenotype . Under this scenario, it has been amply recognized that new antiviral strategies must be investigated to avoid or minimize the selection of drug or multi-drug-escape mutants, and the consequent treatment failure. Strategies already implemented or under development are combination therapies, splitting of treatment between an induction and a maintenance regimen, use of drugs that target cellular functions, and combination of immunotherapy and chemotherapy. As reviewed in , none of these strategies is free of the problem of selection of escape mutants.
An additional strategy now under investigation is lethal mutagenesis, also termed virus entry into error catastrophe, in recognition of its conceptual origins. It consists in achieving large reductions of viral load and ideally virus extinction by increasing the mutation rate of the virus above a critical error rate that sets a limit for virus viability. Current research involves the use of mutagenic base or nucleoside analogues which are converted intracellularly in the nucleoside-triphosphate derivatives which are incorporated into viral RNA during elongation. They do not act as chain terminators, a mechanism that results mainly in inhibition, but they allow continued chain elongation, a mechanism that results in mutagenesis. The latter is a result of the ambiguous pairing with the corresponding complementary purine or pyrimidine nucleotides, when the analogue is either a substrate or a template residue . Lethal mutagenesis was inspired in the concept of crossing an error threshold, or transition into error catastrophe, established as an important corollary of quasispecies theory [42,43]. Crossing the error threshold implies loss of genetic information. It was reasoned that drugs that increase the mutation rate of a virus above a viability threshold may highly diminish the chances of virus escape. Mutagenesis can provide an advantage over conventional non-mutagenic inhibitors because mutagenized genomes may suppress the most infective subpopulations of genomes coexisting in the same quasispecies, as discussed in the next section. A number of base and nucleoside analogues are currently under development as potential new antiviral mutagenic agents [44,45,46,47,48,49,50].
At present it is not known whether in the context of a clinical application of lethal mutagenesis , mutagen-resistant mutants will be as readily selected as inhibitor-resistant mutants. Rib-resistant mutants have been isolated in cell culture [52,53,54,55,56,57,58,59,60,61,62,63,64,65], and in patients subjected to Rib monotherapy . Rib resistance can have multiple mechanisms, as evidenced by the fact that resistance mutations have been mapped in several viral genes. When resistance is associated with amino acid substitutions in the polymerase, it can be due to restoration of polymerase activity or to alterations of nucleotide recognition. The latter can occur through at least three mechanisms: average increase of template-copying fidelity, specific decrease of Rib-triphosphate incorporation (without a significant effect on general fidelity), or modulation of the transition types produced in the presence of Rib (without alteration of the average mutation frequency among the components of the mutant spectrum) [55,57,58,59,61].
LCMV has had an important contribution regarding the feasibility of a lethal mutagenesis-based approach in vivo , and in the proposal of the lethal defection model of virus extinction (participation of defective viruses in decrease of replicative competence of a viral quasispecies ), two of the highlights of lethal mutagenesis research (Table 1). In addition, early experiments evidenced that LCMV could be efficiently extinguished by enhanced mutagenesis  (comment by Eigen ). The transition towards extinction did not involve any modification of the consensus genomic sequence, and entailed a 102- to 103-fold decrease in specific infectivity of LCMV . These were revealing observations to interpret the molecular events associated with virus extinction.
|Table 1. Some highlights in letahal mutagenesis research|
|Observation and implications||References|
|• J.J. Holland and colleagues explore for the first time quasispecies error catastrophe with real viruses and show that poliovirus and vesicular stomatitis virus have very limited tolerance to increased mutagenesis.|||
|This study was the birth of experimental studies on the application of the concept of error catastrophe developed by M. Eigen, P. Schuster and colleagues.|
|• L.A. Loeb, J. Mullins and colleagues show that a mutagenic pyrimidine analogue impairs HIV-1 replication in cell culture. They coin the term “lethal mutagenesis”.|||
|This study suggested the use of mutagenic agents as antiretroviral drugs.|
|• E. Domingo, P. Lowenstein and colleagues show that lymphocytic choriomeningitis virus and foot-and-mouth disease virus can be extinguished by mutagenic agents, and that low viral load and low viral fitness favor extinction.||[35,71]|
|These experiments suggested that modification of virus population parameters, specifically a decrease in fitness and low viral load, may help in producing virus extinction.|
|• S. Crotty, R. Andino, C.E. Cameron and colleagues demonstrate that the antiviral ribonucleoside analogue ribavirin is mutagenic for poliovirus.|||
|This important discovery implied that ribavirin might be exerting some of its antiviral clinical activity as a mutagen. This is still a debated issue, but there is evidence that ribavirin is mutagenic for a number of RNA viruses including LCMV.|
|• 5-Fluorouracil impeded the establishment of a persistent LCMV infection in mice.|||
|This experiment constitutes a proof of principle of the feasibility of a lethal mutagenesis-based antiviral approach in vivo.|
|• Experimental and theoretical evidence for the lethal defection model of virus extinction.|||
|These results introduced the concept that a mutagenic agent may not only “kill” virus but that, more subtly, the agent may be generating interfering genomes that participate in the impairment of viral replication and eventual extinction. The results suggested also the possibility of guiding internal interactions within mutant spectra to achieve extinction through modest mutagenic intensities.|
|• When a mutagen participates in therapy, a sequential inhibitor-mutagen administration might have an advantage over the corresponding combination treatment.||[73,74,75]|
|These studies illustrate that the interactions among drugs must be considered with regard to efficacy, in particular in the case of antiviral inhibitors used with virus-specific mutagenic agents. The general advantage of a combination therapy need not apply when a mutagen is involved in therapy.|
|• 5-Azacytidine can induce lethal mutagenesis of HIV-1|||
|This result suggests that some nucleotide analogues can be incorporated both into RNA and DNA during the retroviral life cycle. It shows also that there is room for classic antiviral and anti-cancer agents to find an application in lethal mutagenesis.|
|• First clinical trial involving administration of a pyrimidine analogue to AIDS patients. The resident HIV-1 was mutagenized although no virus extinction was achieved.|||
|In addition to representing the first clinical trial based on lethal mutagenesis, this result opens the possibility of improved efficacy in vivo using either combination or sequential administration of inhibitors and mutagens, in conjunction with provirus mobilization from carrier cells, a point under active investigation.|
5. Concluding remarks
Quasispecies did not exist as a scientific concept until 1971, when Manfred Eigen published his pioneer treatise . Since its completion by Eigen and Schuster , the theory has been extended to finite populations of replicons under non-equilibrium conditions, and several of its ground-breaking predictions (adaptability, limitations for sustained maintenance of information, ensembles of mutants as units of selection, etc.) have been applied and confirmed with complex biological entities such as the RNA viruses, with their highly compact genomes. Despite many unknowns in viral dynamics, the new insight provided by quasispecies is now permeating several aspects of RNA virus biology, including medical aspects such as the design of antiviral therapies. Treatment of arenavirus infections may also benefit from these developments.
Conflict of Interest
The authors declare no conflict of interest.
We thank several colleagues for important contributions and discussions on lethal mutagenesis and LCMV, in particular John Holland who initiated this line of experimental research. Work in Madrid supported by grant BFU2011-23604 to E.D. and RyC-2010-06516 and AGL-2011-25025 to V.M. and by Fundación R. Areces. The Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is funded by Instituto de Salud Carlos III. H.M. was supported by a predoctoral contract from Instituto de Salud Carlos III (FI08-00775). A.G.-P. acknowledges grant P09-CV1-5428 from Junta de Andalucía.
- Oldstone, M.B.A. Arenaviruses I and III. Current Topics in Microbiol. and Immunol: Berlin, Heidelberg, 2002; Volume Vol. 262 and 263. Springer-Verlag.
- Buchmeier, M.J.; de la Torre, J.C.; Peters, C.J. Arenaviridae: the viruses and their replication. D.M. Knipe P.M., Howley, et al, Eds.; Lappincott Williams & Wilkins: Phyladelphia, 2007; pp. 1791–1827.
- Briese, T.; Paweska, J.T.; McMullan, L.K.; Hutchison, S.K.; Street, C.; Palacios, G.; Khristova, M.L.; Weyer, J.; Swanepoel, R.; Egholm, M.; Nichol, S.T.; Lipkin, W.I. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 2009, 5, e1000455.
- Goeijenbier, M.; Wagenaar, J.; Goris, M.; Martina, B.; Henttonen, H.; Vaheri, A.; Reusken, C.; Hartskeerl, R.; Osterhaus, A.; Van Gorp, E. Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable - epidemiology, diagnostics and treatment. Critical reviews in microbiology 2012. in press.
- Barton, L.L. Lymphocytic choriomeningitis virus: a neglected central nervous system pathogen. Clin. Infect. Dis. 1996, 22, 197, doi:10.1093/clinids/22.1.197.
- Fischer, S.A.; Graham, M.B.; Kuehnert, M.J.; Kotton, C.N.; Srinivasan, A.; Marty, F.M.; Comer, J.A.; Guarner, J.; Paddock, C.D.; DeMeo, D.L.; Shieh, W.J.; Erickson, B.R.; Bandy, U.; DeMaria, A., Jr.; Davis, J.P.; Delmonico, F.L.; Pavlin, B.; Likos, A.; Vincent, M.J.; Sealy, T.K.; Goldsmith, C.S.; Jernigan, D.B.; Rollin, P.E.; Packard, M.M.; Patel, M.; Rowland, C.; Helfand, R.F.; Nichol, S.T.; Fishman, J.A.; Ksiazek, T.; Zaki, S.R. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 2006, 354, 2235–2249.
- Jamieson, D.J.; Kourtis, A.P.; Bell, M.; Rasmussen, S.A. Lymphocytic choriomeningitis virus: an emerging obstetric pathogen? Am. J. Obstet. Gynecol. 2006, 194(6), 1532–1536.
- Palacios, G.; Druce, J.; Du, L.; Tran, T.; Birch, C.; Briese, T.; Conlan, S.; Quan, P.L.; Hui, J.; Marshall, J.; Simons, J.F.; Egholm, M.; Paddock, C.D.; Shieh, W.J.; Goldsmith, C.S.; Zaki, S.R.; Catton, M.; Lipkin, W.I. A new arenavirus in a cluster of fatal transplant-associated diseases. N. Engl. J. Med. 2008, 358, 991–998, doi:10.1056/NEJMoa073785.
- Ambrosio, A.; Saavedra, M.; Mariani, M.; Gamboa, G.; Maiza, A. Argentine hemorrhagic fever vaccines. Human vaccines 2011, 7, 694–700, doi:10.4161/hv.7.6.15198.
- Goicochea, M.A.; Zapata, J.C.; Bryant, J.; Davis, H.; Salvato, M.S.; Lukashevich, I.S. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine 2012, 30, 1445–1452, doi:10.1016/j.vaccine.2011.12.134.
- Sepulveda, C.S.; Garcia, C.C.; Fascio, M.L.; D'Accorso, N.B.; Docampo Palacios, M.L.; Pellon, R.F.; Damonte, E.B. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral. Res. 2012, 93, 16–22, doi:10.1016/j.antiviral.2011.10.007.
- Mendenhall, M.; Russell, A.; Smee, D.F.; Hall, J.O.; Skirpstunas, R.; Furuta, Y.; Gowen, B.B. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS neglected tropical diseases 2011, 5, e1342, doi:10.1371/journal.pntd.0001342.
- Gowen, B.B.; Smee, D.F.; Wong, M.H.; Hall, J.O.; Jung, K.H.; Bailey, K.W.; Stevens, J.R.; Furuta, Y.; Morrey, J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008, 3, e3725.
- McCormick, J.B.; King, I.J.; Webb, P.A.; Scribner, C.L.; Craven, R.B.; Johnson, K.M.; Elliott, L.H.; Belmont-Williams, R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314, 20–26, doi:10.1056/NEJM198601023140104.
- Domingo, E.; Sheldon, J.; Perales, C. Viral quasispecies evolution. Microbiology and Molecular Biology Reviews 2012, 76, 159–216, doi:10.1128/MMBR.05023-11.
- Jabara, C.B.; Jones, C.D.; Roach, J.; Anderson, J.A.; Swanstrom, R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 2011, 108, 20166–20171.
- Fernandez, G.; Clotet, B.; Martinez, M.A. Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J. Virol. 2007, 81, 2485–2496, doi:10.1128/JVI.01594-06.
- Ciurea, A.; Klenerman, P.; Hunziker, L.; Horvath, E.; Senn, B.M.; Ochsenbein, A.F.; Hengartner, H.; Zinkernagel, R.M. Viral persistence in vivo through selection of neutralizing antibody- escape variants. Proc. Natl. Acad. Sci. USA 2000, 97, 2749–2754.
- Aebischer, T.; Moskophidis, D.; Rohrer, U.H.; Zinkernagel, R.M.; Hengartner, H. In vitro selection of lymphocytic choriomeningitis virus escape mutants by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1991, 88, 11047–11051, doi:10.1073/pnas.88.24.11047.
- Ahmed, R.; Hahn, C.S.; Somasundaram, T.; Villarete, L.; Matloubian, M.; Strauss, J.H. Molecular basis of organ-specific selection of viral variants during chronic infection. J. Virol. 1991, 65, 4242–4247.
- Ahmed, R.; Simon, R.S.; Matloubian, M.; Kolhekar, S.R.; Southern, P.J.; Freedman, D.M. Genetic analysis of in vivo-selected viral variants causing chronic infection: importance of mutation in the L RNA segment of lymphocytic choriomeningitis virus. J. Virol. 1988, 62, 3301–3308.
- Buesa-Gomez, J.; Teng, M.N.; Oldstone, C.E.; Oldstone, M.B.; de la Torre, J.C. Variants able to cause growth hormone deficiency syndrome are present within the disease-nil WE strain of lymphocytic choriomeningitis virus. J. Virol. 1996, 70, 8988–8992.
- Ciurea, A.; Hunziker, L.; Martinic, M.M.; Oxenius, A.; Hengartner, H.; Zinkernagel, R.M. CD4+ T-cell-epitope escape mutant virus selected in vivo. Nat. Med. 2001, 7, 795–800, doi:10.1038/89915.
- Dockter, J.; Evans, C.F.; Tishon, A.; Oldstone, M.B. Competitive selection in vivo by a cell for one variant over another: implications for RNA virus quasispecies in vivo. J. Virol. 1996, 70, 1799–1803.
- Evans, C.F.; Borrow, P.; de la Torre, J.C.; Oldstone, M.B. Virus-induced immunosuppression: kinetic analysis of the selection of a mutation associated with viral persistence. J. Virol. 1994, 68, 7367–7373.
- Matloubian, M.; Kolhekar, S.R.; Somasundaram, T.; Ahmed, R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 1993, 67, 7340–7349.
- Matloubian, M.; Somasundaram, T.; Kolhekar, S.R.; Selvakumar, R.; Ahmed, R. Genetic basis of viral persistence: single amino acid change in the viral glycoprotein affects ability of lymphocytic choriomeningitis virus to persist in adult mice. J. Exp. Med. 1990, 172, 1043–1048, doi:10.1084/jem.172.4.1043.
- Pircher, H.; Moskophidis, D.; Rohrer, U.; Burki, K.; Hengartner, H.; Zinkernagel, R.M. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990, 346, 629–633, doi:10.1038/346629a0.
- Salvato, M.; Borrow, P.; Shimomaye, E.; Oldstone, M.B. Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J. Virol. 1991, 65, 1863–1869.
- Teng, M.N.; Borrow, P.; Oldstone, M.B.; de la Torre, J.C. A single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with the ability to cause growth hormone deficiency syndrome. J. Virol. 1996, 70, 8438–8443.
- Hunziker, L.; Ciurea, A.; Recher, M.; Hengartner, H.; Zinkernagel, R.M. Public versus personal serotypes of a viral quasispecies. Proc. Natl. Acad. Sci. USA 2003, 100, 6015–6020, doi:10.1073/pnas.1031671100.
- Teng, M.N.; Oldstone, M.B.; de la Torre, J.C. Suppression of lymphocytic choriomeningitis virus-induced growth hormone deficiency syndrome by disease-negative virus variants. Virology 1996, 223, 113–119, doi:10.1006/viro.1996.0460.
- Sevilla, N.; Domingo, E.; de la Torre, J.C. Contribution of LCMV towards deciphering biology of quasispecies in vivo. Curr. Top. Microbiol. Immunol. 2002, 263, 197–220, doi:10.1007/978-3-642-56055-2_10.
- Sevilla, N.; de la Torre, J.C. Arenavirus Diversity And Evolution: Quasispecies In Vivo. Cur. Top. Microbiol. Immunol. 2006, Vol. 299, 315–335.
- Grande-Pérez, A.; Sierra, S.; Castro, M.G.; Domingo, E.; Lowenstein, P.R. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. USA 2002, 99, 12938–12943, doi:10.1073/pnas.182426999.
- Grande-Pérez, A.; Gómez-Mariano, G.; Lowenstein, P.R.; Domingo, E. Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J. Virol. 2005, 79, 10451–10459, doi:10.1128/JVI.79.16.10451-10459.2005.
- Ruiz-Jarabo, C.M.; Ly, C.; Domingo, E.; de la Torre, J.C. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003, 308, 37–47, doi:10.1016/S0042-6822(02)00046-6.
- Martin, V.; Abia, D.; Domingo, E.; Grande-Perez, A. An interfering activity against lymphocytic choriomeningitis virus replication associated with enhanced mutagenesis. J. Gen. Virol. 2010, 91, 990–1003, doi:10.1099/vir.0.017053-0.
- Moreno, H.; Gallego, I.; Sevilla, N.; de la Torre, J.C.; Domingo, E.; Martin, V. Ribavirin can be mutagenic for arenaviruses. J. Virol. 2011, 85, 7246–7255, doi:10.1128/JVI.00614-11.
- Moreno, H.; Tejero, H.; de la Torre, J.C.; Domingo, E.; Martin, V. Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection. PLoS One 2012, 7, e32550.
- Graci, J.D.; Cameron, C.E. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol. 2008, 3, 553–566, doi:10.2217/174607126.96.36.1993.
- Eigen, M.; Schuster, P. The hypercycle. A principle of natural self-organization. Springer: Berlin, 1979.
- Biebricher, C.K.; Eigen, M. The error threshold. Virus Res. 2005, 107, 117–127, doi:10.1016/j.virusres.2004.11.002.
- Clay, P.G.; McRae, M.; Laurent, J.P. Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults. J. Int. Assoc. Physicians AIDS Care (Chic) 2011, 10, 232–238, doi:10.1177/1545109711406442.
- Harris, K.S.; Brabant, W.; Styrchak, S.; Gall, A.; Daifuku, R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005, 67, 1–9, doi:10.1016/j.antiviral.2005.03.004.
- Hicks, C.; Clay, P.; Redfield, R.; Lalezari, J.; Liporace, R.; Schneider, S.; Sension, M.; McRae, M.; Laurent, J.P. Safety, Tolerability, and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral-Experienced, HIV Type 1-Infected Subjects. AIDS research and human retroviruses 2012. in press.
- Harki, D.A.; Graci, J.D.; Edathil, J.P.; Castro, C.; Cameron, C.E.; Peterson, B.R. Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase. Biochemistry 2007, 8, 1359–1362.
- Harki, D.A.; Graci, J.D.; Galarraga, J.E.; Chain, W.J.; Cameron, C.E.; Peterson, B.R. Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J. Med. Chem. 2006, 49, 6166–6169, doi:10.1021/jm060872x.
- Harki, D.A.; Graci, J.D.; Korneeva, V.S.; Ghosh, S.K.; Hong, Z.; Cameron, C.E.; Peterson, B.R. Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole. Biochemistry 2002, 41, 9026–9033.
- Chu, C.K. Recent advances in nucleosides: Chemistry. and chemotherapy; Elsevier: Amsterdam, 2002.
- Mullins, J.I.; Heath, L.; Hughes, J.P.; Kicha, J.; Styrchak, S.; Wong, K.G.; Rao, U.; Hansen, A.; Harris, K.S.; Laurent, J.P.; Li, D.; Simpson, J.H.; Essigmann, J.M.; Loeb, L.A.; Parkins, J. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS One 2011, 6, e15135.
- Scheidel, L.M.; Durbin, R.K.; Stollar, V. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 1987, 158, 1–7, doi:10.1016/0042-6822(87)90230-3.
- Scheidel, L.M.; Stollar, V. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 1991, 181, 490–499, doi:10.1016/0042-6822(91)90881-B.
- Rosenblum, C.I.; Stollar, V. SVMPA, a mutant of sindbis virus resistant to mycophenolic acid and ribavirin, shows an increased sensitivity to chick interferon. Virology 1999, 259, 228–233, doi:10.1006/viro.1999.9775.
- Agudo, R.; Ferrer-Orta, C.; Arias, A.; de la Higuera, I.; Perales, C.; Perez-Luque, R.; Verdaguer, N.; Domingo, E. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog. 2010, 6, e1001072, doi:10.1371/journal.ppat.1001072.
- Pfeiffer, J.K.; Kirkegaard, K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. USA 2003, 100, 7289–7294, doi:10.1073/pnas.1232294100.
- Pfeiffer, J.K.; Kirkegaard, K. Increased fidelity reduces poliovirus fitness under selective pressure in mice. PLoS Pathog. 2005, 1, 102–110.
- Vignuzzi, M.; Stone, J.K.; Arnold, J.J.; Cameron, C.E.; Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006, 439, 344–348, doi:10.1038/nature04388.
- Arias, A.; Arnold, J.J.; Sierra, M.; Smidansky, E.D.; Domingo, E.; Cameron, C.E. Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J. Virol. 2008, 82, 12346–12355.
- Ferrer-Orta, C.; Sierra, M.; de la Higuera, I.; Agudo, R.; Arias, A.; Perez-Luque, R.; Escarmis, C.; Domingo, E.; Verdaguer, N. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J. Virol. 2010, 84, 6188–6199.
- Sierra, M.; Airaksinen, A.; González-López, C.; Agudo, R.; Arias, A.; Domingo, E. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 2007, 81, 2012–2024, doi:10.1128/JVI.01606-06.
- Feigelstock, D.A.; Mihalik, K.B.; Feinstone, S.M. Selection of hepatitis C virus resistant to ribavirin. Virology journal 2011, 8, 402, doi:10.1186/1743-422X-8-402.
- Coffey, L.L.; Beeharry, Y.; Borderia, A.V.; Blanc, H.; Vignuzzi, M. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc. Natl. Acad. Sci. USA 2011, 108, 16038–16043.
- Pfeiffer, J.K.; Kirkegaard, K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 2005, 79, 2346–2355, doi:10.1128/JVI.79.4.2346-2355.2005.
- Levi, L.I.; Gnadig, N.F.; Beaucourt, S.; McPherson, M.J.; Baron, B.; Arnold, J.J.; Vignuzzi, M. Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog. 2010, 6, e1001163, doi:10.1371/journal.ppat.1001163.
- Young, K.C.; Lindsay, K.L.; Lee, K.J.; Liu, W.C.; He, J.W.; Milstein, S.L.; Lai, M.M. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003, 38, 869–878.
- Grande-Pérez, A.; Lazaro, E.; Lowenstein, P.; Domingo, E.; Manrubia, S.C. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. USA 2005, 102, 4448–4452.
- Eigen, M. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. USA 2002, 99, 13374–13376, doi:10.1073/pnas.212514799.
- Holland, J.J.; Domingo, E.; de la Torre, J.C.; Steinhauer, D.A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 1990, 64, 3960–3962.
- Loeb, L.A.; Essigmann, J.M.; Kazazi, F.; Zhang, J.; Rose, K.D.; Mullins, J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. USA 1999, 96, 1492–1497.
- Sierra, S.; Dávila, M.; Lowenstein, P.R.; Domingo, E. Response of foot-and-mouth disease virus to increased mutagenesis. Influence of viral load and fitness in loss of infectivity. J. Virol. 2000, 74, 8316–8323.
- Crotty, S.; Maag, D.; Arnold, J.J.; Zhong, W.; Lau, J.Y.N.; Hong, Z.; Andino, R.; Cameron, C.E. The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. Nature Medicine 2000, 6, 1375–1379, doi:10.1038/82191.
- Perales, C.; Agudo, R.; Tejero, H.; Manrubia, S.C.; Domingo, E. Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog. 2009, 5, e1000658, doi:10.1371/journal.ppat.1000658.
- Perales, C.; Iranzo, J.; Manrubia, S.C.; Domingo, E. The impact of quasispecies dynamics on the use of therapeutics. Trends in microbiology 2012. in press.
- Iranzo, J.; Perales, C.; Domingo, E.; Manrubia, S.C. Tempo and mode of inhibitor-mutagen antiviral therapies: A multidisciplinary approach. Proc. Natl. Acad. Sci. USA 2011, 108, 16008–16013.
- Dapp, M.J.; Clouser, C.L.; Patterson, S.; Mansky, L.M. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J. Virol. 2009, 83, 11950–11958, doi:10.1128/JVI.01406-09.
- Iranzo, J.; Manrubia, S.C. Stochastic extinction of viral infectivity through the action of defectors. Europhys. Lett. 2009, 85, 18001, doi:10.1209/0295-5075/85/18001.
- Turner, P.E.; Chao, L. Prisoner's dilemma in an RNA virus. Nature 1999, 398, 441–443, doi:10.1038/18913.
- Wilke, C.O.; Reissig, D.D.; Novella, I.S. Replication at periodically changing multiplicity of infection promotes stable coexistence of competing viral populations. Evolution Int. J. Org. Evolution 2004, 58, 900–905.
- Perales, C.; Mateo, R.; Mateu, M.G.; Domingo, E. Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J. Mol. Biol. 2007, 369, 985–1000, doi:10.1016/j.jmb.2007.03.074.
- Youngner, J.S.; Whitaker-Dowling, P. Interference. In Encyclopedia of Virology; Granoff, A., Webster, R.G., Eds.; Academic Press: San Diego, California, 1999; Volume Vol. 2, pp. 850–854.
- de la Torre, J.C.; Holland, J.J. RNA virus quasispecies populations can suppress vastly superior mutant progeny. J. Virol. 1990, 64, 6278–6281.
- Chumakov, K.M.; Powers, L.B.; Noonan, K.E.; Roninson, I.B.; Levenbook, I.S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. USA 1991, 88, 199–203.
- Crowder, S.; Kirkegaard, K. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nature Genetics 2005, 37, 701–709, doi:10.1038/ng1583.
- González-López, C.; Arias, A.; Pariente, N.; Gómez-Mariano, G.; Domingo, E. Preextinction viral RNA can interfere with infectivity. J. Virol. 2004, 78, 3319–3324, doi:10.1128/JVI.78.7.3319-3324.2004.
- Perales, C.; Lorenzo-Redondo, R.; López-Galíndez, C.; Martínez, M.A.; Domingo, E. Mutant spectra in virus behavior. Future Virology 2010, 5, 679–698, doi:10.2217/fvl.10.61.
- Ojosnegros, S.; Perales, C.; Mas, A.; Domingo, E. Quasispecies as a matter of fact: viruses and beyond. Virus. Res. 2011, 162, 203–215, doi:10.1016/j.virusres.2011.09.018.
- Xiang, D.; Sharma, V.R.; Freter, C.E.; Yan, J. Anti-tumor Monoclonal Antibodies in Conjunction with beta-Glucans: a Novel Anti-cancer Immunotherapy. Current medicinal chemistry 2012. in press.
- Murphy, C.G.; Morris, P.G. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anti-cancer drugs 2012, 23, 765–776, doi:10.1097/CAD.0b013e328352d292.
- Pariente, N.; Sierra, S.; Lowenstein, P.R.; Domingo, E. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J. Virol. 2001, 75, 9723–9730, doi:10.1128/JVI.75.20.9723-9730.2001.
- Tapia, N.; Fernandez, G.; Parera, M.; Gomez-Mariano, G.; Clotet, B.; Quinones-Mateu, M.; Domingo, E.; Martinez, M.A. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 2005, 338, 1–8, doi:10.1016/j.virol.2005.05.008.
- Agudo, R.; Arias, A.; Pariente, N.; Perales, C.; Escarmis, C.; Jorge, A.; Marina, A.; Domingo, E. Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J. Mol. Biol. 2008, 382, 652–666, doi:10.1016/j.jmb.2008.07.033.
- Perales, C.; Agudo, R.; Domingo, E. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS ONE 2009, 4, e5554.
- Dapp, M.J.; Holtz, C.M.; Mansky, L.M. Concomitant lethal mutagenesis of human immunodeficiency virus type 1. J. Mol. Biol. 2012, 419, 158–170, doi:10.1016/j.jmb.2012.03.003.
- Torella, J.P.; Chait, R.; Kishony, R. Optimal drug synergy in antimicrobial treatments. PLoS computational biology 2010, 6, e1000796, doi:10.1371/journal.pcbi.1000796.
- Pasquato, A.; Rochat, C.; Burri, D.J.; Pasqual, G.; de la Torre, J.C.; Kunz, S. Evaluation of the anti-arenaviral activity of the subtilisinkexin isozyme-1/site-1 protease inhibitor PF-429242. Virology 2012, 423, 14–22, doi:10.1016/j.virol.2011.11.008.
- Kolokoltsov, A.A.; Adhikary, S.; Garver, J.; Johnson, L.; Davey, R.A.; Vela, E.M. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin. Arch. Virol. 2012, 157, 121–127, doi:10.1007/s00705-011-1115-8.
- Lee, A.M.; Pasquato, A.; Kunz, S. Novel approaches in anti-arenaviral drug development. Virology 2011, 411, 163–169, doi:10.1016/j.virol.2010.11.022.
- Narayanan, A.; Bailey, C.; Kashanchi, F.; Kehn-Hall, K. Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses. Expert. Opin. Investig. Drugs 2011, 20, 239–254, doi:10.1517/13543784.2011.547852.
- Neuman, B.W.; Bederka, L.H.; Stein, D.A.; Ting, J.P.; Moulton, H.M.; Buchmeier, M.J. Development of peptide-conjugated morpholinooligomers as pan-arenavirus inhibitors. Antimicrob. Agents Chemother. 2011, 55, 4631–4638, doi:10.1128/AAC.00650-11.
- Urata, S.; Yun, N.; Pasquato, A.; Paessler, S.; Kunz, S.; de la Torre, J.C. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 2011, 85, 795–803.
- Eigen, M. Self-organization of matter and the evolution of biological macromolecules. Naturwissenschaften. 1971, 58, 465–523, doi:10.1007/BF00623322.
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).